Empower Early Detection of Lung Diseases
AIRBEST
Overview
Advanced Inflammation Recognition through Breath Sensing Technology (AIRBEST) aims to achieve a cutting edge and revolutionary lung function analyser for detecting lung diseases and achieve a market strategy to bring the solution to every user.
Consortium
3 Partners from Sweden and France:
- GattyInstruments AB
- MG Sustainable Engineering AB
- OLYTHE SAS
Budget
Start Date: 01. September 2024
End Date: 31. August 2027
Budget: € 1,163,490
MG Contribution
MG Sustainable Engineering AB is proud to lead the strategic market entry for AIRBEST. We will focus on conducting in-depth market analysis, crafting a robust business model, forging critical partnerships, and building a commercialization roadmap. We’re committed to ensuring that AIRBEST meets market needs and sets new standards in respiratory diagnostics.
Progress and Impact
The technological and commercialization feasibility of the AIRBEST technology will be extensively studies with a strong methodological structure through three phases within the project: Design and Development of a Medical Device, System Development of a Cloud-Based Measuring System, Business Plan and Go-to Market Strategy. AIRBEST generates impact in a multitude of areas and sectors. It can be grouped into four different main impact groups to technological, societal, economic, and sustainability impacts.